Price
No data yet.
Signal Score (90d)
108Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-12.88M | $-5.47 |
| 2024 | $0.00 | $-9.83M | $-1.02 |
| 2023 | $0.00 | $-9.29M | $-1.05 |
| 2022 | $0.00 | $-10.08M | $-1.16 |
| 2021 | $0.00 | $-7.44M | $-1.99 |
Social Signal Score
Earnings
Tue, Nov 17(in 3 months)
Consensus estimate $-0.78 per share
Typical surprise -167.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.89 vs $-0.72miss
- Thu, May 14$-4.00 vs $-0.78miss
- Tue, Feb 24$-6.66 vs $-4.71miss
- Wed, Nov 12$-3.97 vs $-0.82miss
- Wed, Aug 13$-5.61 vs $-4.19miss
- Tue, May 13$-4.32 vs $-0.80miss
Estimates and results for ARTL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ARTL officers and directors.
No open-market trades in the recent filings. All 97 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
97 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Valuation
ARTLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·5h ago·Neutral
…of ART27.13 Expected to Extend Patent Protection for ART27.13 through 2041 SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a U.S. patent application covering…
View source ↗